# ‚öîÔ∏è CLINICAL TRIAL DOSSIER

**NCT ID**: NCT01021579  
**Trial Title**: Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study  
**Patient ID**: ayesha_001  
**Generated**: 2025-11-14T19:58:03.556492  
**Generated By**: JR2 (Dossier Sidekick)

---

## 1. TRIAL OVERVIEW

**Title**: Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study  
**Phase**:   
**Status**: COMPLETED  
**Sponsor**:   
**Estimated Enrollment**: 0  
**Primary Endpoint**: None

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT01021579

---

## 2. ELIGIBILITY ASSESSMENT

**Summary**: 3/6 criteria met

### Eligibility Criteria Table

| Criterion | Status | Confidence | Notes |
|-----------|--------|------------|-------|
| Disease Match | ‚ùå FAIL | 0.00 | No match: ["polycystic ovary syndrome"] vs ovarian_cancer_hgs |
| Treatment Line | ‚úÖ PASS | 0.80 | Line match assumed (not explicitly excluded) |
| Biomarker Requirements | ‚úÖ PASS | 1.00 | No biomarker requirements |
| Location (NYC Metro) | ‚úÖ PASS | 0.50 | No location data (assume match) |
| Inclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * All patients should have at least two of three following criteria: I) chronic anovulation, II) clinical and/or biochemical evidence of androgen excess and III) polycystic-appearing ovaries on transv... |
| Exclusion Criteria (Full Text Available) | üìã REVIEW | 0.80 | See full text: * Patients with Cushing's syndrome, hyperprolactinemia, diabetes mellitus (DM), thyroid disease, adrenal hyperplasia and androgen-secreting tumors or other endocrinopathies, will be excluded from the ... |

---

## 3. STRATEGIC SCENARIOS

### Best Case

**Eligibility Probability**: 50.0%

**Scenario**: All pending biomarker tests return favorable results

**Eligibility Level**: HIGH

### Most Likely

**Eligibility Probability**: 50.0%

**Scenario**: 50% of pending tests pass, some may require additional screening

**Eligibility Level**: MODERATE

### Challenge

**Eligibility Probability**: 50.0%

**Scenario**: Some pending tests fail, may need alternative trials

**Eligibility Level**: LOW

---

## 4. TACTICAL RECOMMENDATIONS

| Action | Lab | Cost | Timeline | Priority | Rationale |
|--------|-----|------|----------|----------|----------|
| Proceed with trial enrollment | N/A | N/A | Immediate | HIGH | All eligibility criteria met |

---

## 5. DRUG MECHANISMS

### Metformin

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Metformin

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

### Metfomin

**Mechanism (Technical)**: [NEEDS VERIFICATION] Mechanism not found in database for Metfomin

**Mechanism (Layman)**: [NEEDS VERIFICATION] Please consult oncologist for mechanism explanation.

**Evidence Tier**: UNKNOWN

---

## 6. LOCATION DETAILS

No location data available.

---

## 7. TIMELINE

**Study Start Date**: 

**Primary Completion Date**: 

---

## 8. FULL ELIGIBILITY TEXT

### Inclusion Criteria

* All patients should have at least two of three following criteria: I) chronic anovulation, II) clinical and/or biochemical evidence of androgen excess and III) polycystic-appearing ovaries on transvaginal ultrasound.

### Exclusion Criteria

* Patients with Cushing's syndrome, hyperprolactinemia, diabetes mellitus (DM), thyroid disease, adrenal hyperplasia and androgen-secreting tumors or other endocrinopathies, will be excluded from the study.
* Patients with adrenal hyperplasia will be excluded by ACTH-stimulated 17-hydroxyprogesterone levels less than 10 ng/ml (15), and ACTH-stimulated 11-deoxycortisol levels less than 21 ng/ml \[3-fold the 95th percentile (16) of a historical control group of 60 healthy women controls\].
* Those subjects who have kidney or liver diseases and those who were smoker or had breast cancer will also be excluded from the study.
* None of the participants receive oral contraceptives (OCPs), steroid hormones or any medications that interfere with lipid metabolism, ovarian and pituitary and hypothalamic function, or insulin sensitivity in the last 3 months before study.

---

## 9. CONTACT INFORMATION

Contact information not available.

---

## 10. PROVENANCE

**Generated By**: JR2

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION]

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

